All > Tricuspid Regurgitation > Sacramento

Edwards EVOQUE System for Tricuspid Valve Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Tricuspid Valve Disease+5 MoreEdwards EVOQUE System - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test how safe and effective the Edwards EVOQUE tricuspid valve replacement system is.

Eligible Conditions
  • Tricuspid Valve Disease
  • Tricuspid Valve Regurgitation
  • Heart Failure
  • Tricuspid Regurgitation
  • Cardiovascular Disease
  • Heart Valve Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
CorMatrix Cor TRICUSPID ECM Valve
1
Active
1
Artisan Aphakia Intraocular Lens

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: 1 year

1 year
Composite endpoint including all-cause mortality, RVAD implantation or heart transplant, tricuspid valve intervention, heart failure hospitalizations, KCCQ improvement, NYHA functional class improvement, and 6-minute walk distance improvement
Composite endpoint including reduction in TR grade, change in QOL from baseline, death and heart failure hospitalization, all-cause hospitalization, all-cause mortality, and change in right ventricular end diastolic volume index
30 days
Rate of Major Adverse Events (MAE)
6 months
TR Grade reduction and composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
CorMatrix Cor TRICUSPID ECM Valve
1
Active
1
Artisan Aphakia Intraocular Lens

Trial Design

3 Treatment Groups

Optimal Medical Therapy (OMT)
1 of 3
Edwards EVOQUE System & OMT
1 of 3
Single-Arm Registry
1 of 3

Active Control

Experimental Treatment

820 Total Participants · 3 Treatment Groups

Primary Treatment: Edwards EVOQUE System · No Placebo Group · N/A

Edwards EVOQUE System & OMT
Device
Experimental Group · 1 Intervention: Edwards EVOQUE System · Intervention Types: Device
Single-Arm Registry
Device
Experimental Group · 1 Intervention: Edwards EVOQUE System · Intervention Types: Device
Optimal Medical Therapy (OMT)
Drug
ActiveComparator Group · 1 Intervention: Optimal Medical Therapy · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Edwards LifesciencesLead Sponsor
164 Previous Clinical Trials
58,180 Total Patients Enrolled
1 Trials studying Tricuspid Valve Disease
825 Patients Enrolled for Tricuspid Valve Disease
Susheel Kodali, MDPrincipal InvestigatorColumbia University
4 Previous Clinical Trials
2,487 Total Patients Enrolled
James Gammie, MDPrincipal InvestigatorJohns Hopkins Health System
Vinod Thourani, MDPrincipal InvestigatorPiedmont Heart Institute
7 Previous Clinical Trials
3,469 Total Patients Enrolled
Philipp Lurz, MDPrincipal InvestigatorHerzzentrum Leipzig GmbH
Rebecca Hahn, MDPrincipal InvestigatorColumbia University
1 Previous Clinical Trials
30 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have symptoms of TR despite medical therapy.
Appropriate for transcatheter tricuspid valve replacement per the local heart team.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top